121 related articles for article (PubMed ID: 38598922)
21. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
Rischin D; Migden MR; Lim AM; Schmults CD; Khushalani NI; Hughes BGM; Schadendorf D; Dunn LA; Hernandez-Aya L; Chang ALS; Modi B; Hauschild A; Ulrich C; Eigentler T; Stein B; Pavlick AC; Geiger JL; Gutzmer R; Alam M; Okoye E; Mathias M; Jankovic V; Stankevich E; Booth J; Li S; Lowy I; Fury MG; Guminski A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554615
[TBL] [Abstract][Full Text] [Related]
22. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
Zucali PA; Lin CC; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su WC; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen YC; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; Lépine L; de Bono J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058326
[TBL] [Abstract][Full Text] [Related]
23. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M; Kilickap S; Sezer A; Gümüş M; Bondarenko I; Gogishvili M; Nechaeva M; Schenker M; Cicin I; Ho GF; Kulyaba Y; Zyuhal K; Scheusan RI; Garassino MC; He X; Kaul M; Okoye E; Li Y; Li S; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
Lancet Oncol; 2023 Sep; 24(9):989-1001. PubMed ID: 37591293
[TBL] [Abstract][Full Text] [Related]
24. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Hong DS; Concin N; Vergote I; de Bono JS; Slomovitz BM; Drew Y; Arkenau HT; Machiels JP; Spicer JF; Jones R; Forster MD; Cornez N; Gennigens C; Johnson ML; Thistlethwaite FC; Rangwala RA; Ghatta S; Windfeld K; Harris JR; Lassen UN; Coleman RL
Clin Cancer Res; 2020 Mar; 26(6):1220-1228. PubMed ID: 31796521
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
[No Abstract] [Full Text] [Related]
26. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
[TBL] [Abstract][Full Text] [Related]
27. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
[TBL] [Abstract][Full Text] [Related]
29. Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.
Passarelli A; Pisano C; Coppola E; Ventriglia J; Cecere SC; Di Napoli M; Carideo L; Lastoria S; Pignata S
Front Immunol; 2023; 14():1303893. PubMed ID: 38193091
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study.
An J; Li X; Wang J; Zhu L; An R; Jiang K; Huang Y; Wang K; Li G; Wang C; Yuan J; Hou X; Yang G; Li J; Wang Q; Zhu J; Wu L
Front Immunol; 2023; 14():1142256. PubMed ID: 37153587
[TBL] [Abstract][Full Text] [Related]
32. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Huang X; He M; Peng H; Tong C; Liu Z; Zhang X; Shao Y; Zhu D; Zhang J; Yin JC; Yang F; Lan C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011535
[TBL] [Abstract][Full Text] [Related]
33. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Crinò L; Bidoli P; Delmonte A; Grossi F; De Marinis F; Ardizzoni A; Vitiello F; Lo Russo G; Parra HS; Cortesi E; Cappuzzo F; Calabrò L; Tiseo M; Turci D; Gamucci T; Antonelli P; Morabito A; Chella A; Giannarelli D; Galetta D
Oncologist; 2019 Nov; 24(11):e1165-e1171. PubMed ID: 30996007
[TBL] [Abstract][Full Text] [Related]
34. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
[TBL] [Abstract][Full Text] [Related]
35. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
[TBL] [Abstract][Full Text] [Related]
36. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
[TBL] [Abstract][Full Text] [Related]
37. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Amrane K; Geier M; Corre R; Léna H; Léveiller G; Gadby F; Lamy R; Bizec JL; Goarant E; Robinet G; Gouva S; Quere G; Abgral R; Schick U; Bernier C; Chouaid C; Descourt R
Cancer Med; 2020 Apr; 9(7):2309-2316. PubMed ID: 32022459
[TBL] [Abstract][Full Text] [Related]
38. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
39. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
